TP53 and acute myeloid leukemia: Conversely, TP53-wild-type and R248Q-mutated AML cells displayed enrichment in cellular senescence, heme metabolism, and fatty acid metabolism pathways, suggesting that TP53 mutations may drive metabolic reprogramming, promoting stemness and aggressive disease behavior (101).